339 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
ABT Abbott Laboratories $67.67 $118.71B Downtrend
Article Searches
Zimmer Biomet's (ZBH) Q1 Earnings, Revenues Beat Estimates http://www.zacks.com/stock/news/404555/zimmer-biomets-zbh-q1-earnings-revenues-beat-estimates?cid=CS-ZC-FT-404555 Apr 26, 2019 - While sales in Americas remains dull, Zimmer Biomet (ZBH) is witnessing strength in the Asia Pacific and EMEA regions.
Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Up http://www.zacks.com/stock/news/404475/illumina-ilmn-q1-earnings-beat-estimates-gross-margin-up?cid=CS-ZC-FT-404475 Apr 26, 2019 - Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.
GNC Holdings (GNC) Reports Q1 Earnings, Revenues Down Y/Y http://www.zacks.com/stock/news/404443/gnc-holdings-gnc-reports-q1-earnings-revenues-down-y-y?cid=CS-ZC-FT-404443 Apr 26, 2019 - Despite year-over-year decline in earnings and revenues, better performing International segment and key developments favor GNC Holdings (GNC) in Q1.
Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1 http://www.zacks.com/stock/news/404289/omnicell-omcl-earnings-and-revenues-beat-estimates-in-q1?cid=CS-ZC-FT-404289 Apr 26, 2019 - Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.
Cerner (CERN) Earnings and Revenues Meet Estimates in Q1 http://www.zacks.com/stock/news/404279/cerner-cern-earnings-and-revenues-meet-estimates-in-q1?cid=CS-ZC-FT-404279 Apr 26, 2019 - Cerner (CERN) gains from Professional Services unit in first-quarter 2019. A decline in bookings raises concern.
Solid Sales Growth Makes These 5 Stocks Worth Buying Now http://www.zacks.com/stock/news/399339/solid-sales-growth-makes-these-5-stocks-worth-buying-now?cid=CS-ZC-FT-399339 Apr 25, 2019 - Sales growth is an early indicator of the company's future earnings performance.
Abbott Laboratories (ABT) CEO Miles White on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4254989-abbott-laboratories-abt-ceo-miles-white-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 17, 2019 - Abbott Laboratories (NYSE:ABT) Q1 2019 Earnings Conference Call April 17, 2019 9:00 am ET Company Participants Miles White - Chairman, Chief Executive Officer Robert Ford - President, Chief Operating
Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid http://www.zacks.com/stock/news/386433/abbott-abt-q1-earnings-beat-estimates-organic-sales-solid?cid=CS-ZC-FT-386433 Apr 17, 2019 - Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.
Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip http://www.zacks.com/stock/news/364388/thermo-fisher-to-buy-brammer-bio-tightens-gene-therapy-grip?cid=CS-ZC-FT-364388 Mar 25, 2019 - On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.
Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm http://www.zacks.com/stock/news/364189/abbotts-new-ce-mark-to-boost-core-laboratory-diagnostics-arm?cid=CS-ZC-FT-364189 Mar 25, 2019 - Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.

Pages: 12345678...34

<<<Page 3>